Asthma

GSK to Buy Respiratory Drug Developer Aiolos Bio

GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year, Aiolos is a San Francisco, USA and London, UK-based biopharmaceutical company that develops treatments for respiratory diseases.

Bioelectronic Medicines: A New Type of Personalization